Probe-Based Confocal Laser Endomicroscopy to Guide Real-Time Endoscopic Therapy in Barrett's Esophagus with Dysplasia by Johnson, Eric A. et al.
 
Case Rep Gastroenterol 2012;6:285–292 
DOI: 10.1159/000338835 
Published online: 
May 23, 2012 
© 2012 S. Karger AG, Basel 
ISSN 1662–0631 
www.karger.com/crg 
This is an Open Access article licensed under the terms of the Creative Commons 
Attribution-NonCommercial-NoDerivs 3.0 License (www.karger.com/OA-license), applicable 
to the online version of the article only. Distribution for non-commercial purposes only.   
 
                      Deepak V. Gopal, MD, FRCP(C), 
FASGE 
  Division of Gastroenterology and Hepatology 
School of Medicine and Public Health, University of Wisconsin, 4223 MFCB 
1685 Highland Avenue, Madison, WI 53705 (USA) 
Tel. +1 608 263 4033, E-Mail dvg @ medicine.wisc.edu 
 
285 
   
Probe-Based Confocal Laser 
Endomicroscopy to Guide 
Real-Time Endoscopic Therapy 
in Barrett’s Esophagus with 
Dysplasia 
Eric A. Johnson
a    Ryan De Lee
a    Rashmi Agni
b    
Patrick Pfau
a    Mark Reichelderfer
a    Deepak V. Gopal
a 
aDivision of Gastroenterology and Hepatology and 
bDepartment of Pathology 
and Laboratory Medicine, School of Medicine and Public Health, University of 
Wisconsin, Madison, Wisc., USA 
 
 
Key Words 
Barrett’s esophagus · Probe-based confocal laser · Endomicroscopy · High-grade 
dysplasia · Low-grade dysplasia 
 
 
Abstract 
Probe-based confocal laser endomicroscopy (pCLE) is a novel imaging technique which 
utilizes a low-power laser light passed through a fiber-optic bundle, within a miniprobe that 
is advanced into the working channel, to obtain microscopic images of the mucosa. This 
allows the endoscopist to evaluate the microarchitecture of the gastrointestinal epithelium 
in real time. At this time pCLE cannot replace histopathology, but it can provide diagnostic 
information as well as guide therapeutic management in patients with Barrett’s esophagus 
(BE) with high-grade dysplasia (HGD). We describe a retrospective case series in which four 
patients with BE and biopsy-proven HGD underwent endoscopy with pCLE to direct real-time 
endoscopic ablation therapy and/or endoscopic mucosal resection (EMR), which was 
performed in conjunction with pCLE. All four patients had pCLE showing features of HGD. 
After either EMR or radiofrequency ablation (RFA), pCLE was again used to evaluate the 
margins after therapy to assure accuracy. In one case, pCLE had features of dysplasia at the 
margin and further repeat EMR was immediately performed. Another case had a 
normal-appearing esophagus, but pCLE found features of BE in discrete areas and targeted 
biopsies were performed, which confirmed BE. This patient subsequently underwent RFA 
therapy of the residual areas of BE. In conclusion, in patients with BE and dysplasia, pCLE is 
an effective tool used to target biopsies, guide endoscopic therapy and assess the accuracy 
of EMR or RFA. 
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Introduction 
Confocal laser endomicroscopy (CLE) is a novel imaging technique which utilizes a 
low-power laser light passed through a fiber-optic bundle to obtain microscopic images 
of the mucosa. This allows the endoscopist to evaluate the microarchitecture of the 
epithelium and lamina propria in real time and can provide in vivo, real-time diagnostic 
information and also guide therapeutic management. To obtain these high-contrast 
images, CLE requires contrast injection prior to imaging with an agent such as 
fluorescein, which has been shown to be safe in several studies [1–3]. There are 
currently two devices for CLE, one in which the laser is integrated into the distal tip of 
an upper endoscope or colonoscope and allows full use of the working channel at the 
same time (developed by Pentax, Tokyo, Japan). The second system, called probe-based 
confocal laser endomicroscopy (pCLE; Cellvizio, Mauna Kea Technologies, Paris, 
France) utilizes a confocal miniprobe which is passed down the working channel of a 
conventional endoscope, including the side viewing endoscope [4]. In other works, 
pCLE has been used to distinguish between hyperplastic, adenomatous and neoplastic 
colon polyps, and to evaluate early gastric cancers, celiac sprue, pancreatic neoplasms, 
biliary diseases and Barrett’s esophagus (BE) [5–10]. 
BE is defined as metaplasia of the esophageal epithelium with replacement of the 
normal squamous epithelium by columnar epithelium containing goblet cells. These 
changes are also referred to as intestinal metaplasia [11]. BE is associated with an 
increased risk of developing esophageal adenocarcinoma, the incidence of which has 
increased dramatically over the past several decades [12–16]. Once diagnosed, 
esophageal adenocarcinoma has a poor prognosis with a less than a 25% five-year 
survival after a diagnosis of locally advanced disease [17]. BE can range from having no 
histologic evidence of cellular atypia (nondysplastic metaplasia) to low-grade dysplasia 
(LGD) on through to high-grade dysplasia (HGD). The efficacy of Barrett’s surveillance 
to detect early neoplasia is controversial and the optimal care of patients with 
dysplastic BE is unclear, but improvement in surveillance techniques may improve 
sensitivity and also guide endoscopic management of these neoplastic lesions. There 
have been several recent developments in endoscopic therapy of LGD, HGD and 
intramucosal carcinoma using combined techniques of endoscopic mucosal resection 
(EMR) and endoscopic ablation therapies such as radiofrequency ablation (RFA). More 
recently, an international prospective randomized controlled trial by Sharma et al. [18] 
concluded that pCLE combined with high-definition white light examination (HD-WLE) 
significantly improved the ability to detect neoplasia in BE patients compared with 
HD-WLE alone. The authors suggested that this finding may allow better informed 
decisions to be made for the management and subsequent treatment of BE patients. In 
this article, we describe a retrospective case series in which four patients (table 1) 
with BE and biopsy-proven HGD underwent endoscopy with pCLE to direct real-time 
endoscopic ablation therapy and/or EMR, which was performed in conjunction with 
real-time pCLE. 
Patients and Methods 
All endoscopies and pCLE were performed under general anesthesia by one experienced 
gastroenterologist (D.V.G.). A standard upper endoscopy (esophagogastroduodenoscopy) was first 
performed in all cases with WLE using a high-definition diagnostic upper endoscope (EG2990i HD;  
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Pentax of America, Montvale, N.J., USA). pCLE was then performed after intravenous injection of 
2.5 ml of 10% fluorescein. A GastroFlex UHD Confocal MiniprobeTM (Cellvizio, Mauna Kea 
Technologies) was inserted through the working channel of the endoscope and the probe was 
positioned on the margins of the previously resected area to examine for areas of intestinal 
metaplasia, dysplasia, and early cancer. 
The examiner was trained on the CLE criteria for assessment of BE, dysplasia, and esophageal 
neoplasm. During the procedure, foci were characterized by pCLE as having normal squamous 
epithelium, Barrett’s metaplasia, or dysplasia. Normal esophageal mucosa has stacked layers of 
squamous epithelium, while Barrett’s metaplasia appears as organized columnar epithelium with a 
regular vascular pattern, normal villous gland architecture, and with dark, hypodense round 
structures representing goblet cells. LGD, HGD and neoplasm are a continuum characterized by 
progressively increasing cellular disorganization, variable cell height/thickness, disruption of normal 
villous gland pattern and fusion of glands.  
Results 
Case 1 
A 71-year-old male patient was referred with a 4 cm segment of BE with 
biopsy-proven LGD demonstrated 1 year earlier. A repeat 6 month surveillance 
endoscopy confirmed the diagnosis of BE with LGD. Subsequent follow-up endoscopy 
revealed two noncontiguous sub-centimeter regions of nodularity within the Barrett’s 
segment. The nodularity was addressed with EMR via the Wilson-Cook Duette band 
ligation and snare system (Duette multiband mucosectomy, Cook Medical, Winston 
Salem, N.C., USA); three resections were performed. Pathology demonstrated HGD 
extending to the margins of the resected specimen. After careful discussion, the patient 
decided to proceed with endoscopic treatment. A repeat endoscopy again 
demonstrated a single sub-centimeter region of nodularity within the BE segment 
(fig. 1a). pCLE was then performed on the distal esophagus. The esophageal nodularity 
was evaluated by positioning the tip of the confocal miniprobe on the suspicious lesion 
and corresponding images demonstrated dysplasia embedded within intestinal 
metaplasia. EMR of the mucosal nodularity was performed. pCLE was again employed 
along the resection margins. Inspection demonstrated irregular glands and cellular 
disorganization consistent with dysplasia (fig. 1b). As further dysplasia was identified 
and there were concerns for residual mucosal nodularity at the margin, further EMR 
overlapping adjacent to the original dysplastic resection margin was performed, and 
follow-up pathology confirmed HGD (fig. 1c). pCLE was again used to evaluate the 
margins of the resection and demonstrated intestinal metaplasia without residual 
dysplasia. Endoscopically, there appeared to be complete mucosal resection of the 
nodular area. Following EMR, during the same endoscopic session HALO-90TM 
(Halo 360 and Halo 90, BARRX, Sunnyvale, Calif., USA) RFA was performed on the 
remaining Barrett’s segment. After the ablation therapy was performed, pCLE was 
simultaneously employed in the esophagus alongside the HALO-90 RFA catheter 
confirming eradication of the Barrett’s metaplasia in the treatment zones (fig. 1d). Of 
note, this technique was used to aid in the positioning of the HALO-RFA and to assess 
the efficacy of endoscopic therapy, but pCLE images were not acquired during active 
ablation therapy.   
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Case 2 
A 66-year-old male veteran with a 3 cm segment of BE presented with 
biopsy-proven HGD. Medical comorbidities were felt to preclude esophagectomy. A 
surveillance examination demonstrated a 1 cm segment of nodular Barrett’s mucosa. 
The nodule was removed via EMR again using the Wilson-Cook Duette system. 
Pathology confirmed HGD. Based on the size of the defect, RFA on the remaining 
Barrett’s tissue was deferred. On subsequent examination, there was new nodularity 
appreciated at the gastroesophageal junction embedded within a Barrett’s field. EMR 
was performed in a near circumferential manner around the gastroesophageal 
junction; four resections were performed. Pathology later confirmed HGD. RFA was 
again deferred based on the extent of resection. On a subsequent examination, no 
further nodularity was identified. pCLE was performed, revealing evidence of dysplasia 
within a larger contiguous 3 cm segment of intestinal metaplasia. RFA was performed 
on the Barrett’s segment. Again, as in the first case, post treatment pCLE was performed 
with the probe placed along the HALO-90 RFA catheter, which demonstrated successful 
ablation therapy with no further remaining zones of residual dysplasia or Barrett’s 
metaplasia. A 2-month surveillance endoscopic examination revealed significant 
regression of the Barrett’s segment. However, there was a new contiguous 1-cm region 
of nodular Barrett’s mucosa in the distal esophagus. pCLE demonstrated evidence of 
dysplasia within the nodular segment. Adjacent mucosa demonstrated changes 
consistent with intestinal metaplasia. EMR was performed on the nodular segment in a 
semi-circumferential manner; three resections were performed. Repeat pCLE 
demonstrated no evidence of residual dysplasia at the resection margins.  
Case 3 
An 80-year-old woman with a history of long-segment BE (11 cm) with 
biopsy-proven multifocal HGD was referred to our institution for therapy. The patient 
had significant medical comorbidities including coronary artery disease, atrial 
fibrillation and cerebrovascular/peripheral vascular disease. She declined 
esophagectomy. In the prior year, she underwent HALO-360 RFA amidst three 
independent EMR treatments for nodular Barrett’s with biopsy-proven HGD. pCLE was 
applied to the nodular mucosa, demonstrating evidence of HGD prior to EMR. A 
subsequent endoscopic evaluation demonstrated persistent, 5-cm-long segment BE 
without nodularity with earlier biopsies confirming regression to LGD. pCLE was 
performed on the Barrett’s mucosa, demonstrating areas of intestinal metaplasia with 
features of dysplasia. HALO-360 RFA was applied to the entire 11 cm Barrett’s segment. 
After HALO-360 ablation treatment was performed, the pCLE probe was introduced 
alongside and proximal to the HALO-360 balloon probe and the margin without 
evidence of intestinal metaplasia at the proximal ablation margins and cautery artifact 
consistent with treatment at the ablation zone. Again, it should be made clear that pCLE 
images were not obtained during active therapy. A 2-month follow-up protocol 
endoscopy demonstrated endoscopic regression of Barrett’s with only residual islands 
seen, consistent with biopsy-proven intestinal metaplasia without dysplasia. 
Case 4 
A 67-year-old man presented with a longstanding history of endoscopically treated 
long-segment BE with biopsy-proven LGD and a focus of HGD. Surveillance biopsies 
following HALO-360 RFA demonstrated a focus of LGD in a residual region of Barrett’s  
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metaplasia at the distal esophagus. pCLE was performed, demonstrating features of 
dysplasia at the Barrett’s segment. EMR was performed during the same endoscopic 
session using the Wilson-Cook Duette system; two resections were performed. 
Pathology confirmed a focus of HGD with surrounding LGD confined to the EMR 
nodular specimen without involvement of the resection margins. pCLE performed post 
EMR demonstrated only features of intestinal metaplasia without dysplasia. Again 
during the same endoscopic session, HALO-90 RFA was performed on residual islands 
of Barrett’s mucosa in the distal esophagus, and real-time pCLE performed just after 
ablation therapy, with the probe based along the HALO-90 RFA catheter, did not 
demonstrate residual metaplasia or dysplasia. A subsequent surveillance examination 
3 months later showed significant endoscopic regression with an irregular Z line, but 
without visual evidence of continuous BE. Few scattered islands were noted and pCLE 
was performed, demonstrating evidence of intestinal metaplasia without dysplasia. 
Target biopsies were performed and follow-up HALO-90 RFA was applied to treat 
residual metaplasia. Biopsy results confirmed intestinal metaplasia with no residual 
dysplasia.  
Discussion 
The role of BE surveillance and treatment of dysplasia in the setting of BE are still 
being debated, however mounting evidence shows that endoscopic therapy is a viable, 
and perhaps preferable, alternative to both surgery and surveillance in patients with 
HGD or early carcinoma [19–21]. This retrospective case series provides evidence that 
the ability of the endoscopists to identify dysplasia in real time using pCLE technology 
allows them to target dysplastic areas for therapeutic treatment, to locate residual 
posttherapeutic areas for re-treatment, and then to confirm that ablated/resected areas 
and margins are free of residual intestinal metaplasia or dysplasia. 
Several studies have shown pCLE to be an important up-and-coming technology in 
the surveillance of BE and identification of dysplasia and early cancer. It is important to 
note that pCLE does not eliminate the need for biopsies, but it does allow for more 
targeted biopsies, potentially leading to a better disease characterization, fewer 
biopsies and more cost-effective surveillance [9, 22, 23]. Konda et al. [8] showed that 
pCLE can be used in real time to provide the endoscopist with additional information to 
aid with targeting EMR and to assess accuracy of EMR. 
We present a case series describing pCLE being used in conjunction with the HALO 
apparatus to target therapy and confirm successful mucosal resection and RFA of 
dysplastic lesions in BE. In each patient described above, the pCLE imaging was used 
prior to endoscopic therapy to identify areas of concern, guide targeted biopsies and 
target additional therapy to that area. pCLE was then used again after both EMR and 
HALO RFA to assess the accuracy and completeness of each therapy (table 2). 
Limitations to this study include the limited number of patients and that using pCLE 
after ablation is not well studied. Moreover, post therapy cauterization effect may make 
it difficult to distinguish whether mucosa is sufficiently ablated; thus, at this time pCLE 
cannot necessarily be used to predict the treatment effect of RFA. 
CLE is an emerging technology with a potential to aid the endoscopist in the 
diagnosis and treatment of several gastrointestinal maladies, including BE, but much  
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research remains to be done. In patients with BE and dysplasia, pCLE is an effective 
tool used to target biopsies, obtain a comprehensive disease characterization, guide 
endoscopic therapy and assess the accuracy of EMR or RFA. This case series can serve 
as the impetus for a pilot study or other large, multicenter, prospective trials to 
establish the feasibility and technique of using real-time pCLE in conjunction with EMR 
and RFA during the same session in order to guide therapy of Barrett’s with dysplasia. 
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Table 1. Baseline patient characteristics 
                        Case  Age  Gender  Length of Barrett’s  Prior dysplasia  
(per biopsy) 
Prior endoscopic 
treatment 
                        1  71  M  4 cm, circumferential  HGD  prior EMR  
                        2  66  M  3 cm, circumferential, few short tongues  HGD  prior EMR 
                        3  80  F  10 cm, circumferential but  
noncontiguous 
LGD and HGD  prior RFA and 
EMR 
                        4  67  M  6 cm (distal 4 cm circumferential, two 
2 cm tongues extending proximally) 
LGD and HGD  prior RFA and 
EMR 
                        M = Male; F = female. 
     
 
Table 2. Summary of results of pCLE findings and endoscopic therapy 
                        Case  WLE findings  pCLE before  Therapy  pCLE after  Pathology 
                        1  <1 cm nodule in field of BE  dysplasia present  EMR and HALO-RFA  dysplasia present after first EMR  confirmed HGD, 
negative margins 
                        2  Nodular mucosa in BE  dysplasia present  EMR with HALO-RFA   no dysplasia after EMR  BE with HGD 
                        3  Nodular mucosa in BE  dysplasia present  EMR  no dysplasia at margins, BE present  BE with HGD 
                        4  History of HGD and BE, but  
no endoscopic BE now 
features of BE  biopsies of suspected BE  not performed  BE confirmed 
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Fig. 1. a Segment of BE with one region of nodularity (arrow). b Endomicroscopy image after EMR 
showing gland irregularity and cellular disorganization, representing residual dysplasia present at 
the resection margin. c Histology showing features of HGD including back-to-back glands, piled up 
nuclei, and loss of polarity (circle). The arrow shows BE without dysplasia. Magnification: ×20. d pCLE 
probe being used alongside the HALO-90 catheter to confirm eradication of dysplasia at margins after 
ablative therapy. 
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